Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review

Author:

Vulto Arnold G.ORCID,Vanderpuye-Orgle Jackie,van der Graaff Martin,Simoens Steven R. A.ORCID,Dagna Lorenzo,Macaulay Richard,Majeed Beenish,Lemay Jeffrey,Hippenmeyer Jane,Gonzalez-McQuire Sebastian

Abstract

Introduction: Biosimilars have the potential to enhance the sustainability of evolving health care systems. A sustainable biosimilars market requires all stakeholders to balance competition and supply chain security. However, there is significant variation in the policies for pricing, procurement, and use of biosimilars in the European Union. A modified Delphi process was conducted to achieve expert consensus on biosimilar market sustainability in Europe. Methods: The priorities of 11 stakeholders were explored in three stages: a brainstorming stage supported by a systematic literature review (SLR) and key materials identified by the participants; development and review of statements derived during brainstorming; and a facilitated roundtable discussion. Results: Participants argued that a sustainable biosimilar market must deliver tangible and transparent benefits to the health care system, while meeting the needs of all stakeholders. Key drivers of biosimilar market sustainability included: (i) competition is more effective than regulation; (ii) there should be incentives to ensure industry investment in biosimilar development and innovation; (iii) procurement processes must avoid monopolies and minimize market disruption; and (iv) principles for procurement should be defined by all stakeholders. However, findings from the SLR were limited, with significant gaps on the impact of different tender models on supply risks, savings, and sustainability. Conclusions: A sustainable biosimilar market means that all stakeholders benefit from appropriate and reliable access to biological therapies. Failure to care for biosimilar market sustainability may impoverish biosimilar development and offerings, eventually leading to increased cost for health care systems and patients, with fewer resources for innovation.

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference31 articles.

1. Biosimilars Markethttps://www.marketdataforecast.com/market-reports/biosimilars-market

2. Global Biosimilars Market 2018–2022https://www.technavio.com/report/global-biosimilars-market-analysis-share-2018?tnplus

3. Biosimilars—Position Paper. Updating Position Statement from the European League against Rheumatism (EULAR) Standing Committee of People with Arthritis/Rheumatism in Europe (PARE)https://www.eular.org/myUploadData/files/biosimilars_paper_updated_2018_09_14_dw.pdf

4. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

5. European Commission. Biosimilars in the EU. Information Guide for Healthcare Professionalshttps://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3